Prestige Consumer Analyst Ratings
DA Davidson Upgrades Prestige Consumer Healthcare to Buy From Neutral, Adjusts Price Target to $93 From $65
Canadian Investment Banking Group: Maintaining the Prestige Consumer (PBH.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $80.00 to $80.00.
Prestige Consumer Analyst Ratings
DA Davidson: Maintaining the Prestige Consumer (PBH.US) rating, adjusted from neutral to neutral, and adjusted the target price from $65.00 to $65.00.
Prestige Consumer Analyst Ratings
DA Davidson Maintains Neutral on Prestige Consumer, Maintains $65 Price Target
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), Prestige Consumer Healthcare (PBH) and CervoMed (CRVO)
Analysts Are Bullish on Top Healthcare Stocks: Nyxoah (NYXH), Prestige Consumer Healthcare (PBH)
Analysts Are Bullish on These Healthcare Stocks: Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL)
D.A. Davidson Sticks to Their Hold Rating for Prestige Consumer Healthcare (PBH)
Premium Brands Hldgs Analyst Ratings
Analysts Offer Insights on Consumer Goods Companies: Prestige Consumer Healthcare (PBH) and Beyond Meat (BYND)
Canaccord Genuity Sticks to Its Buy Rating for Prestige Consumer Healthcare (PBH)
Premium Brands Hldgs Analyst Ratings
DA Davidson Reiterates Neutral on Prestige Consumer, Maintains $60 Price Target
Prestige Consumer Healthcare (PBH) Was Upgraded to a Hold Rating at D.A. Davidson
National Bank Notes Progress by Premium Brands Holdings, Cuts Price Target on Higher Leverage
D.A. Davidson Keeps Their Hold Rating on Prestige Consumer Healthcare (PBH)
DA Davidson Reiterates Neutral on Prestige Consumer, Maintains $60 Price Target